These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 8847018)
21. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251 [TBL] [Abstract][Full Text] [Related]
22. [The treatment of carcinoid of the small intestine with octreotide and alpha-interferon. A call for participation in a randomized study]. Ahrén B Dtsch Med Wochenschr; 1996 May; 121(22):744-5. PubMed ID: 8646989 [No Abstract] [Full Text] [Related]
23. Ileal carcinoid tumors stimulating Crohn's disease: incidence among 176 consecutive cases of ileal carcinoid. Hsu EY; Feldman JM; Lichtenstein GR Am J Gastroenterol; 1997 Nov; 92(11):2062-5. PubMed ID: 9362193 [TBL] [Abstract][Full Text] [Related]
24. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Campana D; Nori F; Pezzilli R; Piscitelli L; Santini D; Brocchi E; Corinaldesi R; Tomassetti P Endocr Relat Cancer; 2008 Mar; 15(1):337-42. PubMed ID: 18310299 [TBL] [Abstract][Full Text] [Related]
25. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219 [TBL] [Abstract][Full Text] [Related]
26. Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumours. Rohaizak M; Farndon JR ANZ J Surg; 2002 Sep; 72(9):635-8. PubMed ID: 12269913 [TBL] [Abstract][Full Text] [Related]
27. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Frank M; Klose KJ; Wied M; Ishaque N; Schade-Brittinger C; Arnold R Am J Gastroenterol; 1999 May; 94(5):1381-7. PubMed ID: 10235222 [TBL] [Abstract][Full Text] [Related]
28. Carcinoid of the pancreas. Migliori M; Tomassetti P; Lalli S; Casadei R; Santini D; Corinaldesi R; Gullo L Pancreatology; 2002; 2(2):163-6. PubMed ID: 12123097 [TBL] [Abstract][Full Text] [Related]
29. Medical treatment of neuroendocrine gut and pancreatic tumors. Oberg K; Eriksson B Acta Oncol; 1989; 28(3):425-31. PubMed ID: 2472826 [TBL] [Abstract][Full Text] [Related]
30. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors. Berković MC; Altabas V; Herman D; Hrabar D; Goldoni V; Vizner B; Zjacić-Rotkvić V Coll Antropol; 2007 Jun; 31(2):531-4. PubMed ID: 17847934 [TBL] [Abstract][Full Text] [Related]
31. [Therapy of metastatic carcinoid with the somatostatin analog octreotide and with recombinant interferon alfa 2b]. Linkesch M; Kuzmits R; Geyer G Wien Klin Wochenschr; 1989 Jun; 101(13):455-7. PubMed ID: 2763566 [TBL] [Abstract][Full Text] [Related]
32. Neurokinin A monitoring of response to interferon alpha in a patient with an advanced small bowel neuroendocrine tumour uncontrolled by somatostatin analogue therapy. Ardill JE; Johnston BT; McCance DR; Eatock M Ann Clin Biochem; 2017 Mar; 54(2):297-301. PubMed ID: 27638929 [TBL] [Abstract][Full Text] [Related]
33. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors. Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995 [TBL] [Abstract][Full Text] [Related]
35. Carcinoid tumors--somatostatine in the diagnosis and therapy. Kinova S; Duris I; Kratochvilova E; Ondrejka P; Payer J Bratisl Lek Listy; 2002; 103(3):108-12. PubMed ID: 12190042 [TBL] [Abstract][Full Text] [Related]
36. [Treatment with octreotide (SMS 201-995) in a case of intestinal carcinoid tumor]. Goñi F; Oleaga A; Goñi MJ; Monreal M; Yoldi A; González A; Llorente I; Moncada E Rev Clin Esp; 1991 Nov; 189(7):331-4. PubMed ID: 1722585 [TBL] [Abstract][Full Text] [Related]
37. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Arnold R; Rinke A; Klose KJ; Müller HH; Wied M; Zamzow K; Schmidt C; Schade-Brittinger C; Barth P; Moll R; Koller M; Unterhalt M; Hiddemann W; Schmidt-Lauber M; Pavel M; Arnold CN Clin Gastroenterol Hepatol; 2005 Aug; 3(8):761-71. PubMed ID: 16234004 [TBL] [Abstract][Full Text] [Related]
38. Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors. Schell SR; Camp ER; Caridi JG; Hawkins IF J Gastrointest Surg; 2002; 6(5):664-70. PubMed ID: 12399054 [TBL] [Abstract][Full Text] [Related]
39. Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study. Jacobsen MB; Hanssen LE; Kolmannskog F; Schrumpf E; Vatn MH; Bergan A Scand J Gastroenterol; 1995 Aug; 30(8):789-96. PubMed ID: 7481548 [TBL] [Abstract][Full Text] [Related]
40. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]